Articles related to BIOSIMILARS

Amid emerging safety concerns, ADC Therapeutics has paused its mid-stage trial of Zynlonta, a potential game-changer in treating certain types of blood cancer, calling into question the drug’s future trajectory.

In the US, the use of biosimilars is becoming more and more important because of the potential for cost savings to increase patient access to biologic medicines and lower total healthcare expenditures. Healthcare professionals and patients have been the subjects of surveys on biosimilars, but recent comprehensive quantitative data about US pharmacists’ attitudes toward and comprehension of biosimilars are scarce. The majority of US pharmacists understood the fundamental ideas behind biosimilar drugs; however, certain knowledge gaps were concentrated in the areas of interchangeability and substitution. Only slightly more than half of those surveyed said they felt confident answering patients’ inquiries about biosimilars. To bridge these gaps and boost confidence in administering biosimilars, US pharmacists need additional and targeted instructional techniques.

In 2023, patents for the two blockbusters Humira and Stelara will expire. The patents for Aranesp, Rituxan, Simponi, and others will expire in 2024, and in 2025, six more blockbuster drugs will experience patent expiration, opening the field to a rush of biosimilars. That could create an environment of significantly reduced drug prices.